View Item 

Show simple item record

2020 American College of Rheumatology Guideline for the Management of Gout

dc.contributor.authorFitzGerald, John D.
dc.contributor.authorDalbeth, Nicola
dc.contributor.authorMikuls, Ted
dc.contributor.authorBrignardello‐petersen, Romina
dc.contributor.authorGuyatt, Gordon
dc.contributor.authorAbeles, Aryeh M.
dc.contributor.authorGelber, Allan C.
dc.contributor.authorHarrold, Leslie R.
dc.contributor.authorKhanna, Dinesh
dc.contributor.authorKing, Charles
dc.contributor.authorLevy, Gerald
dc.contributor.authorLibbey, Caryn
dc.contributor.authorMount, David
dc.contributor.authorPillinger, Michael H.
dc.contributor.authorRosenthal, Ann
dc.contributor.authorSingh, Jasvinder A.
dc.contributor.authorSims, James Edward
dc.contributor.authorSmith, Benjamin J.
dc.contributor.authorWenger, Neil S.
dc.contributor.authorBae, Sangmee Sharon
dc.contributor.authorDanve, Abhijeet
dc.contributor.authorKhanna, Puja P.
dc.contributor.authorKim, Seoyoung C.
dc.contributor.authorLenert, Aleksander
dc.contributor.authorPoon, Samuel
dc.contributor.authorQasim, Anila
dc.contributor.authorSehra, Shiv T.
dc.contributor.authorSharma, Tarun Sudhir Kumar
dc.contributor.authorToprover, Michael
dc.contributor.authorTurgunbaev, Marat
dc.contributor.authorZeng, Linan
dc.contributor.authorZhang, Mary Ann
dc.contributor.authorTurner, Amy S.
dc.contributor.authorNeogi, Tuhina
dc.date.accessioned2020-06-03T15:23:07Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2020-06-03T15:23:07Z
dc.date.issued2020-06
dc.identifier.citationFitzGerald, John D.; Dalbeth, Nicola; Mikuls, Ted; Brignardello‐petersen, Romina ; Guyatt, Gordon; Abeles, Aryeh M.; Gelber, Allan C.; Harrold, Leslie R.; Khanna, Dinesh; King, Charles; Levy, Gerald; Libbey, Caryn; Mount, David; Pillinger, Michael H.; Rosenthal, Ann; Singh, Jasvinder A.; Sims, James Edward; Smith, Benjamin J.; Wenger, Neil S.; Bae, Sangmee Sharon; Danve, Abhijeet; Khanna, Puja P.; Kim, Seoyoung C.; Lenert, Aleksander; Poon, Samuel; Qasim, Anila; Sehra, Shiv T.; Sharma, Tarun Sudhir Kumar; Toprover, Michael; Turgunbaev, Marat; Zeng, Linan; Zhang, Mary Ann; Turner, Amy S.; Neogi, Tuhina (2020). "2020 American College of Rheumatology Guideline for the Management of Gout." Arthritis Care & Research (6): 744-760.
dc.identifier.issn2151-464X
dc.identifier.issn2151-4658
dc.identifier.urihttps://hdl.handle.net/2027.42/155497
dc.publisherWiley Periodicals, Inc.
dc.publisherCasper Pharma
dc.title2020 American College of Rheumatology Guideline for the Management of Gout
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelGeriatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155497/1/acr24180_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/155497/2/acr24180.pdf
dc.identifier.doi10.1002/acr.24180
dc.identifier.sourceArthritis Care & Research
dc.identifier.citedreferenceJanssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double- blind, randomised equivalence trial. Lancet 2008; 371: 1854 - 60.
dc.identifier.citedreferenceUS Food and Drug Administration. FDA adds boxed warning for increased risk of death with gout medicine Uloric (febuxostat). URL: https://www.fda.gov/drugs/- drug-safety-and-avail- abili- ty/fda-adds-boxed-warni- ng-incre- ased-risk-death-gout-medic- ine-uloric-febux- ostat.
dc.identifier.citedreferenceWhite WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018; 378: 1200 - 10.
dc.identifier.citedreferenceZhang M, Solomon DH, Desai RJ, Kang EH, Liu J, Neogi T, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. Circulation 2018; 138: 1116 - 26.
dc.identifier.citedreferenceFoody J, Turpin RS, Tidwell BA, Lawrence D, Schulman KL. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. Am Health Drug Benefits 2017; 10: 393 - 401.
dc.identifier.citedreferencePerez- Ruiz F, Hernandez- Baldizon S, Herrero- Beites AM, Gonzalez- Gay MA. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res (Hoboken) 2010; 62: 1299 - 305.
dc.identifier.citedreferenceSaag KG, Fitz- Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, et al. Lesinurad combined with allopurinol: a randomized, double- blind, placebo- controlled study in gout patients with an inadequate response to standard- of- care allopurinol (a US- based study). Arthritis Rheumatol 2017; 69: 203 - 12.
dc.identifier.citedreferenceBecker MA, Baraf HS, Yood RA, Dillon A, Vazquez- Mellado J, Ottery FD, et al. Long- term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 2013; 72: 1469 - 74.
dc.identifier.citedreferenceSolomon DH, Bitton A, Katz JN, Radner H, Brown EM, Fraenkel L. Treat to target in rheumatoid arthritis: fact, fiction, or hypothesis? [review]. Arthritis Rheumatol 2014; 66: 775 - 82.
dc.identifier.citedreferenceAlloway JA, Moriarty MJ, Hoogland YT, Nashel DJ. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111 - 3.
dc.identifier.citedreferenceSiegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21: 1325 - 7.
dc.identifier.citedreferenceAxelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803 - 5.
dc.identifier.citedreferenceMan CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute gout- like arthritis: a double- blind, randomized, controlled trial. Ann Emerg Med 2007; 49: 670 - 7.
dc.identifier.citedreferenceSo A, De Meulemeester M, Pikhlak A, Yücel AE, Richard D, Murphy V, et al. Canakinumab for the treatment of acute flares in difficult- to- treat gouty arthritis: results of a multicenter, phase II, dose- ranging study. Arthritis Rheum 2010; 62: 3064 - 76.
dc.identifier.citedreferenceSchumacher HR, Berger MF, Li- Yu J, Perez- Ruiz F, Burgos- Vargas R, Li C. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol 2012; 39: 1859 - 66.
dc.identifier.citedreferenceTerkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, et al. Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 2013; 15: R25.
dc.identifier.citedreferenceZhang YK, Yang H, Zhang JY, Song LJ, Fan YC. Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout. Int J Clin Pract 2014; 68: 633 - 8.
dc.identifier.citedreferenceHirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ. Efficacy of canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis- related health outcomes measures. Int J Clin Pract 2014; 68: 1503 - 7.
dc.identifier.citedreferenceSchlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active- controlled, double- blind trials and their initial extensions. Ann Rheum Dis 2012; 71: 1839 - 48.
dc.identifier.citedreferenceSchlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V, et al. Canakinumab relieves symptoms of acute flares and improves health- related quality of life in patients with difficult- to- treat gouty arthritis by suppressing inflammation: results of a randomized, dose- ranging study. Arthritis Res Ther 2011; 13: R53.
dc.identifier.citedreferenceSchlesinger N, Detry MA, Holland BK, Baker DG, Beutler AM, Rull M, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331 - 4.
dc.identifier.citedreferenceMajor TJ, Topless RK, Dalbeth N, Merriman TR. Evaluation of the diet wide contribution to serum urate levels: meta- analysis of population- based cohorts. BMJ 2018; 363: k3951.
dc.identifier.citedreferenceKottgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome- wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013; 45: 145 - 54.
dc.identifier.citedreferenceSpencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis 2012; 71: 1490 - 5.
dc.identifier.citedreferenceRalston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. Br Med J (Clin Res Ed) 1988; 296: 1641 - 2.
dc.identifier.citedreferenceGibson T, Kilbourn K, Horner I, Simmonds HA. Mechanism and treatment of hypertriglyceridaemia in gout. Ann Rheum Dis 1979; 38: 31 - 5.
dc.identifier.citedreferenceNeogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: an internet- based case- crossover study. Am J Med 2014; 127: 311 - 8.
dc.identifier.citedreferenceZhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, et al. Purine- rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012; 71: 1448 - 53.
dc.identifier.citedreferenceHolland R, McGill NW. Comprehensive dietary education in treated gout patients does not further improve serum urate. Intern Med J 2015; 45: 189 - 94.
dc.identifier.citedreferenceStirpe F, Della Corte E, Bonetti E, Abbondanza A, Abbati A, De Stefano F. Fructose- induced hyperuricaemia. Lancet 1970; 2: 1310 - 1.
dc.identifier.citedreferenceChoi JW, Ford ES, Gao X, Choi HK. Sugar- sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2008; 59: 109 - 16.
dc.identifier.citedreferenceChoi HK, Willett W, Curhan G. Fructose- rich beverages and risk of gout in women. JAMA 2010; 304: 2270 - 8.
dc.identifier.citedreferenceSacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al, for the DASH- Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344: 3 - 10.
dc.identifier.citedreferenceNielsen SM, Bartels EM, Henriksen M, Waehrens EE, Gudbergsen H, Bliddal H, et al. Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. Ann Rheum Dis 2017; 76: 1870 - 82.
dc.identifier.citedreferenceNguyen UD, Zhang Y, Louie- Gao Q, Niu J, Felson DT, LaValley MP, et al. Obesity paradox in recurrent attacks of gout in observational studies: clarification and remedy. Arthritis Care Res (Hoboken) 2017; 69: 561 - 6.
dc.identifier.citedreferenceDalbeth N, Chen P, White M, Gamble GD, Barratt- Boyes C, Gow PJ, et al. Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study. Ann Rheum Dis 2014; 73: 797 - 802.
dc.identifier.citedreferenceRomero- Talamas H, Daigle CR, Aminian A, Corcelles R, Brethauer SA, Schauer PR. The effect of bariatric surgery on gout: a comparative study. Surg Obes Relat Dis 2014; 10: 1161 - 5.
dc.identifier.citedreferenceDessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539 - 43.
dc.identifier.citedreferenceStamp LK, O’Donnell JL, Frampton C, Drake JM, Zhang M, Chapman PT. Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial. Arthritis Rheum 2013; 65: 1636 - 42.
dc.identifier.citedreferenceDaskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161 - 75.
dc.identifier.citedreferenceMiao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non- insulin- dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 2011; 58: 2 - 7.
dc.identifier.citedreferenceWaldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L, et al. Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post- hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol 2018; 6: 310 - 8.
dc.identifier.citedreferenceFitzGerald JD, Mikuls TR, Neogi T, Singh JA, Robbins M, Khanna PP, et al. Development of the American College of Rheumatology electronic clinical quality measures for gout. Arthritis Care Res (Hoboken) 2018; 70: 659 - 71.
dc.identifier.citedreferencePerez- Ruiz F, Calabozo M, Pijoan JI, Herrero- Beites AM, Ruibal A. Effect of urate- lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356 - 60.
dc.identifier.citedreferenceKhan AA, Quinn TJ, Hewitt J, Fan Y, Dawson J. Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta- analysis. Age (Dordr) 2016; 38: 16.
dc.identifier.citedreferenceLevy G, Shi JM, Cheetham TC, Rashid N. Urate- lowering therapy in moderate to severe chronic kidney disease. Perm J 2018; 22: 17 - 142.
dc.identifier.citedreferenceAbeles AM, Pillinger MH. Gout and cardiovascular disease: crystallized confusion. Curr Opin Rheumatol 2019; 31: 118 - 24.
dc.identifier.citedreferenceDoherty M, Jansen TL, Nuki G, Pascual E, Perez- Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis 2012; 71: 1765 - 70.
dc.identifier.citedreferenceChen- Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007- 2016. Arthritis Rheumatol 2019; 71: 991 - 9.
dc.identifier.citedreferenceRashid N, Coburn BW, Wu YL, Cheetham TC, Curtis JR, Saag KG, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol 2015; 42: 504 - 12.
dc.identifier.citedreferenceSarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006; 81: 925 - 34.
dc.identifier.citedreferenceSingh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007; 57: 822 - 9.
dc.identifier.citedreferenceKhanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1. Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431 - 46.
dc.identifier.citedreferenceKhanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2. Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 - 61.
dc.identifier.citedreferenceRomeijnders AC, Gorter KJ. Summary of the Dutch College of General Practitioners- - Gout- Standard. Ned Tijdschr Geneeskd 2002; 146: 309 - 13. In Dutch.
dc.identifier.citedreferenceZhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II. Management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312 - 24.
dc.identifier.citedreferenceJordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372 - 4.
dc.identifier.citedreferenceRichette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda- Sanabria J, et al. 2016 updated EULAR evidence- based recommendations for the management of gout. Ann Rheum Dis 2017; 76: 29 - 42.
dc.identifier.citedreferenceKuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis 2015; 74: 661 - 7.
dc.identifier.citedreferenceBriesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28: 437 - 43.
dc.identifier.citedreferenceDuarte- Garcia A, Zamore R, Wong JB. The evidence basis for the American College of Rheumatology practice guidelines. JAMA Intern Med 2018; 178: 146 - 8.
dc.identifier.citedreferenceMcLean RM. The long and winding road to clinical guidelines on the diagnosis and management of gout. Ann Intern Med 2017; 166: 73 - 4.
dc.identifier.citedreferenceGuyatt GH, Oxman AD, Vist GE, Kunz R, Falck- Ytter Y, Alonso- Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924 - 6.
dc.identifier.citedreferenceHultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol 2017; 87: 4 - 13.
dc.identifier.citedreferenceAlper BS, Oettgen P, Kunnamo I, Iorio A, Ansari MT, Murad MH, et al. Defining certainty of net benefit: a GRADE concept paper. BMJ Open 2019; 9: e027445.
dc.identifier.citedreferenceDe Lautour H, Dalbeth N, Taylor WJ. Outcome measures for gout clinical trials: a summary of progress. Curr Treatm Opt Rheumatol 2015; 1: 156 - 66.
dc.identifier.citedreferenceTaylor WJ, Brown M, Aati O, Weatherall M, Dalbeth N. Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria? Arthritis Care Res (Hoboken) 2013; 65: 1259 - 64.
dc.identifier.citedreferenceSchunemann HJ, Mustafa RA, Brozek J, Santesso N, Bossuyt PM, Steingart KR, et al. GRADE guidelines: 22. The GRADE approach for tests and strategies- from test accuracy to patient- important outcomes and recommendations. J Clin Epidemiol 2019; 111: 69 - 82.
dc.identifier.citedreferenceBaraf HS, Becker MA, Gutierrez- Urena SR, Treadwell EL, Vazquez- Mellado J, Rehrig CD, et al. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open- label extension in patients with chronic gout refractory to conventional therapy. Arthritis Res Ther 2013; 15: R137.
dc.identifier.citedreferenceStrand V, Khanna D, Singh JA, Forsythe A, Edwards NL. Improved health- related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. J Rheumatol 2012; 39: 1450 - 7.
dc.identifier.citedreferenceSundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez- Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711 - 20.
dc.identifier.citedreferenceTausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, et al. Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6- month phase 3 clinical trial and extension study. Rheumatology (Oxford) 2017; 56: 2170 - 8.
dc.identifier.citedreferenceDalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, et al. Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis Rheumatol 2017; 69: 1903 - 13.
dc.identifier.citedreferenceShoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321 - 5.
dc.identifier.citedreferenceDalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, et al. Effects of febuxostat in early gout: a randomized, double- blind, placebo- controlled study. Arthritis Rheumatol 2017; 69: 2386 - 95.
dc.identifier.citedreferenceLevy GD, Rashid N, Niu F, Cheetham TC. Effect of urate- lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol 2014; 41: 955 - 62.
dc.identifier.citedreferenceLu CC, Wu SK, Chen HY, Chung WS, Lee MC, Yeh CJ. Clinical characteristics of and relationship between metabolic components and renal function among patients with early- onset juvenile tophaceous gout. J Rheumatol 2014; 41: 1878 - 83.
dc.identifier.citedreferenceDalbeth N, House ME, Horne A, Taylor WJ. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet Disord 2013; 14: 363.
dc.identifier.citedreferenceKanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta- analysis. BMC Nephrol 2015; 16: 58.
dc.identifier.citedreferenceCampion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421 - 6.
dc.identifier.citedreferenceGoldfarb DS, MacDonald PA, Gunawardhana L, Chefo S, McLean L. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol 2013; 8: 1960 - 7.
dc.identifier.citedreferenceEttinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986; 315: 1386 - 9.
dc.identifier.citedreferenceLiu P, Wang H, Zhang F, Chen Y, Wang D, Wang Y. The effects of allopurinol on the carotid intima- media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three- year randomized parallel- controlled study. Intern Med 2015; 54: 2129 - 37.
dc.identifier.citedreferenceKimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 2018; 72: 798 - 810.
dc.identifier.citedreferencePerez- Ruiz F, Herrero- Beites AM, Carmona L. A two- stage approach to the treatment of hyperuricemia in gout: the - dirty dish- hypothesis. Arthritis Rheum 2011; 63: 4002 - 6.
dc.identifier.citedreferenceZyloprim (allopurinol) product information. East Brunswick (NJ): Casper Pharma; 2018. URL: https://www.acces- sdata.fda.gov/drugs- atfda_docs/label/- 2018/01608- 4s044- lbl.pdf.
dc.identifier.citedreferenceStamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64: 2529 - 36.
dc.identifier.citedreferenceStamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 2017; 76: 1522 - 8.
dc.identifier.citedreferenceYamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate- lowering therapy: results from FORTUNE- 1, a prospective, multicentre randomised study. Ann Rheum Dis 2018; 77: 270 - 6.
dc.identifier.citedreferencePerez- Ruiz F, Alonso- Ruiz A, Calabozo M, Herrero- Beites A, Garcia- Erauskin G, Ruiz- Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545 - 9.
dc.identifier.citedreferenceDoherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost- effectiveness of nurse- led care involving education and engagement of patients and a treat- to- target urate- lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 2018; 392: 1403 - 12.
dc.identifier.citedreferenceWright DF, Duffull SB, Merriman TR, Dalbeth N, Barclay ML, Stamp LK. Predicting allopurinol response in patients with gout. Br J Clin Pharmacol 2016; 81: 277 - 89.
dc.identifier.citedreferenceStamp LK, Chapman PT, Barclay M, Horne A, Frampton C, Tan P, et al. Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open- label extension study. Ann Rheum Dis 2017; 76: 2065 - 70.
dc.identifier.citedreferenceBorstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31: 2429 - 32.
dc.identifier.citedreferenceMitha E, Schumacher HR, Fouche L, Luo SF, Weinstein SP, Yancopoulos GD, et al. Rilonacept for gout flare prevention during initiation of uric acid- lowering therapy: results from the PRESURGE- 2 international, phase 3, randomized, placebo- controlled trial. Rheumatology (Oxford) 2013; 52: 1285 - 92.
dc.identifier.citedreferencePaulus HE, Schlosstein LH, Godfrey RG, Klinenberg JR, Bluestone R. Prophylactic colchicine therapy of intercritical gout: a placebo- controlled study of probenecid- treated patients. Arthritis Rheum 1974; 17: 609 - 14.
dc.identifier.citedreferencePoiley J, Steinberg AS, Choi YJ, Davis CS, Martin RL, McWherter CA, et al. A randomized, double- blind, active- and placebo- controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout. Arthritis Rheumatol 2016; 68: 2027 - 34.
dc.identifier.citedreferenceSchlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double- blind, randomised study. Ann Rheum Dis 2011; 70: 1264 - 71.
dc.identifier.citedreferenceSchumacher HR Jr, Evans RR, Saag KG, Clower J, Jennings W, Weinstein SP, et al. Rilonacept (interleukin- 1 trap) for prevention of gout flares during initiation of uric acid- lowering therapy: results from a phase III randomized, double- blind, placebo- controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 2012; 64: 1462 - 70.
dc.identifier.citedreferenceSundy JS, Schumacher HR, Kivitz A, Weinstein SP, Wu R, King- Davis S, et al. Rilonacept for gout flare prevention in patients receiving uric acid- lowering therapy: results of RESURGE, a phase III, international safety study. J Rheumatol 2014; 41: 1703 - 11.
dc.identifier.citedreferenceSolomon DH, Liu CC, Kuo IH, Zak A, Kim SC. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis 2016; 75: 1674 - 9.
dc.identifier.citedreferenceYu J, Qiu Q, Liang L, Yang X, Xu H. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real- world clinical setting. Mod Rheumatol 2018; 28: 339 - 44.
dc.identifier.citedreferenceBecker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450 - 61.
dc.identifier.citedreferenceSchumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28- week, phase III, randomized, double- blind, parallel- group trial. Arthritis Rheum 2008; 59: 1540 - 8.
dc.identifier.citedreferenceHill EM, Sky K, Sit M, Collamer A, Higgs J. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015; 21: 120 - 5.
dc.identifier.citedreferenceTaylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012; 125: 1126 - 34.e7.
dc.identifier.citedreferenceFeng X, Li Y, Gao W. Significance of the initiation time of urate- lowering therapy in gout patients: a retrospective research. Joint Bone Spine 2015; 82: 428 - 31.
dc.identifier.citedreferenceGoldfien R, Pressman A, Jacobson A, Ng M, Avins A. A pharmacist- staffed, virtual gout management clinic for achieving target serum uric acid levels: a randomized clinical trial. Perm J 2016; 20: 15 - 234.
dc.identifier.citedreferenceMikuls TR, Cheetham TC, Levy GD, Rashid N, Kerimian A, Low KJ, et al. Adherence and outcomes with urate- lowering therapy: a site- randomized trial. Am J Med 2019; 132: 354 - 61.
dc.identifier.citedreferencePhillips LS, Branch WT, Cook CB, Doyle JP, El- Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med 2001; 135: 825 - 34.
dc.identifier.citedreferenceDe Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos- Vargas R, Chapman P, et al. Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises. Arthritis Care Res (Hoboken) 2016; 68: 667 - 72.
dc.identifier.citedreferenceHung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA- B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102: 4134 - 9.
dc.identifier.citedreferenceTassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA- B*5801 and allopurinol- induced Stevens- Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704 - 9.
dc.identifier.citedreferenceGonzalez- Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, da Silva AL, et al. Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucleic Acids Res 2015; 43 ( Database issue ): D784 - 8.
dc.identifier.citedreferenceJutkowitz E, Dubreuil M, Lu N, Kuntz KM, Choi HK. The cost- effectiveness of HLA- B*5801 screening to guide initial urate- lowering therapy for gout in the United States. Semin Arthritis Rheum 2017; 46: 594 - 600.
dc.identifier.citedreferenceKeller SF, Lu N, Blumenthal KG, Rai SK, Yokose C, Choi JW, et al. Racial/ethnic variation and risk factors for allopurinol- associated severe cutaneous adverse reactions: a cohort study. Ann Rheum Dis 2018; 77: 1187 - 93.
dc.identifier.citedreferenceFam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44: 231 - 8.
dc.identifier.citedreferenceSoares J, Caiado J, Lopes A, Pereira BM. Allopurinol desensitization: a fast or slow protocol? J Investig Allergol Clin Immunol 2015; 25: 295 - 7.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr24180_am.pdf
Size:
469.2KB
Format:
PDF
View/Open
Name:
acr24180.pdf
Size:
815.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.